Organisation paid for research Program year 2025 Source: CMS Open Payments

Oncology Hematology

Neither a doctor nor a teaching hospital

Research payments

$85,378

23 payments

Through program year 2025, Oncology Hematology is reported as receiving $85,378 in research payments, across 23 payments.

By program year

7 rows

Year	Kind	Amount	Payments
2025	Research	$9,238	2
2024	Research	$615	1
2023	Research	$11,610	5
2022	Research	$27,307	5
2021	Research	$10,305	1
2020	Research	$21,031	7
2019	Research	$5,272	2

Breakdown

Who paid Research payments · program years 2019–2025

Genentech, Inc. $48,502 13 payments
Pharmacyclics LLC, An AbbVie Company $27,226 4 payments
Novartis Pharmaceuticals Corporation $8,200 5 payments
American Regent $1,450 1 payment

Studies the money was for Research payments · program years 2019–2025

Phase Ib Combo for HER2 BC with Herceptin Kadcyla Perjeta aPDL1 $27,865 7 payments
Study of Ibrutinib and Rituximab in Treatment Na????ve Follicular Lymphoma $27,226 4 payments
My Pathway $9,238 2 payments
Phase III in Cdk4 6 Inhibitor Experienced Pik3ca Mutant HR Her2 Metastatic Breast Cancer $7,528 1 payment
Two Arm Randomized Phase 3 Study in High Risk Nsclc Comparing Canakinumab VS Placebo in Adjuvant Setting $7,293 2 payments
A Phase III Trial of GDC 9545 in Combination With Palbo in HR Her2 Neg 1L MBC $3,790 2 payments
1Vit14039 $1,450 1 payment
An open-label, multi-center, phase II platform study evaluating the efficacy and safety of NIS793 and other new investigational drug combinations with standard of care (SOC) anti-cancer therapy for the second line treatment of metastatic colorectal cancer (mCRC) $870 2 payments
Mytactic Targeting Actionable Mutation Study in Cancer US Piia Multicenter Nonrandomized Open LBL $81 1 payment
A Randomized Double Blind Placebo Controlled Phase III Study Comparing the Combination of Pdr001 Dabrafenib and Trametinib Versus Placebo Dabrafenib and Trametinib in Previously Untreated Patients With Unresectable Or Metastatic Braf V600 Mutant Melanoma $37 1 payment

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.